Men with high estrogen levels could be at greater risk of breast cancer


New research indicates that men with naturally high levels of the female hormone estrogen may have a greater risk of developing breast cancer.

Vaginal lubricant options for women with hormone-receptor positive (HR+) cancer

Vaginal lubricant options for women with hormone-receptor positive (HR+) cancer


What vaginal lubricants are available for for women with hormone-receptor positive (HR+) cancer?

Exercise may lower breast cancer risk by altering estrogen metabolism

Aerobic exercise may reduce breast cancer risk by changing estrogen metabolism to produce more of the metabolites that keep the disease at bay.

Radiation after lumpectomy might benefit older women after all

Most older women with early breast cancer are more likely to avoid mastectomy by following lumpectomy with radiation, contrary to current thinking.

Drug combination extends survival in metastatic breast cancer

Coadministration of anastrozole (Arimidex) and fulvestrant (Faslodex) improved survival in women with HR-positive metastatic breast cancer.

Extra weight reduces effectiveness of estrogen-suppressing therapy

Overweight women with breast cancer were found to have more estrogen remaining after hormone-suppressing therapy than did women of healthy weight.

PET shows early response to hormone therapy in breast cancer

Using positron emission tomography (PET) to image progesterone receptor status in breast tumors may show who on hormone therapy will benefit.

Gene mutations may predict breast CA treatment response

Gene mutations may predict breast CA treatment response

For women with estrogen receptor-positive breast cancer, mutations ID aromatase inhibitor response.

Breast cancer vaccine works better with letrozole than with tamoxifen

A vaccine significantly increased survival in mice with breast cancer when given with the hormonal therapy letrozole, but not with tamoxifen.

AACR: Study links long-term estrogen use to breast cancer

AACR: Study links long-term estrogen use to breast cancer

Risk increased with estrogen, estrogen progesterone; no increase in fatal breast cancer.

Estrogen use after hysterectomy protects against breast cancer

Women who used estrogen after hysterectomy appear to be nearly 25% less likely to develop breast cancer and nearly 63% less likely to die from it.

Stopping hormone therapy may quickly lower breast cancer rates

Discontinuing hormone therapy may lead to tumor regression in breast cancer, indicate the results of a new study.

PET clarifies difficult breast cancer cases


Positron emission tomography (PET) can help pinpoint a breast cancer diagnosis and predict prognosis in an aggressive form of the disease.

Brachytherapy may be overused in breast cancer patients

Many women who underwent accelerated partial breast irradiation using brachytherapy were deemed cautionary or unsuitable for the procedure based on guidelines later issued by ASTRO.

Zoledronic acid continues to improve survival in premenopausal breast cancer

Long-term follow-up data suggest that adjuvant zoledronic acid results in highly significant disease-free and overall survival, mainly in patients with low levels of estrogen.

MRI may be useful as noninvasive test of breast cancer prognosis

MRI measures were related to prognostic tumor markers, suggesting that such imaging can provide valuable noninvasive characterization of tumor biology in people with breast cancer.

Concurrent anastrozole/fulvestrant could be new first-line breast cancer treatment

Administering anastrozole (Arimidex) and fulvestrant (Faslodex) in combination rather than in sequence extended overall survival by 6 months in women with metastatic breast cancer, researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.

Diabetes drug helps prevent growth of breast cancer cells

Metformin, a widely used agent in the treatment of type 2 diabetes, stopped a number of natural and man-made chemicals from stimulating the growth of breast cancer cells.

Entinostat shows which users are most likely to have delayed breast cancer progression

Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.

HRT and breast cancer

GPs should advise women to continue taking HRT, despite claims linking it to breast cancer, according to an expert on the menopause.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs